With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals with 11 manufacturers to develop and manufacture generic versions of a Roche influenza treatment.
Under the agreements, brokered by the Medicines Patent Pool, the companies can develop, manufacture, and supply Xofluza in 129 countries, covering nearly all low- and middle-income nations. The manufacturers will also have access to technical data, reference products for bioequivalence studies, and other support intended to help with regulatory approval in those countries.
This marks the latest effort to widen access for a needed medication to lower-income countries, a goal that has often required the pharmaceutical industry to balance its financial priorities with ensuring its medicines can be affordably obtained by the largest number of patients possible.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
